5 Revealing Analyst Questions From Jazz Pharmaceuticals’s Q2 Earnings Call

Jazz Pharmaceuticals delivered a positive Q2, with a strong 16% year-over-year revenue increase driven primarily by its oncology and rare disease portfolios. Management attributed the quarter’s performance to robust demand for flagship products like Xywav and Epidiolex, as well as accelerating uptake of new oncology therapies. CEO Renée Galá noted, “Our results reflect an intense focus on aligned execution across our diversified portfolio, sustained demand of our commercial products and progress in advancing our long-term priorities for value creation.”

Is now the time to buy JAZZ? Find out in our full research report (it’s free for active Edge members).

While we enjoy listening to the management’s commentary, our favorite part of earnings calls is the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.

Our Top 5 Analyst Questions From Jazz Pharmaceuticals’s Q2 Earnings Call

• Marc Goodman (Leerink): asked about the drivers behind Epidiolex’s quarterly growth and whether inventory or new indications contributed. Chief Commercial Officer Samantha Pearce pointed to strong demand across pediatric and adult segments, with no unusual inventory movements.
• Jessica Fye (JPMorgan): inquired about Jazz’s confidence in zanidatamab’s upcoming approval and the prospects for demonstrating survival benefit in the next interim analysis. Chief Medical Officer Rob Iannone expressed high confidence in approval and cited strong prior interim results.
• Jason Gerberry (Bank of America): questioned the sustainability of Xywav’s performance and the potential impact of generic competition in future years. CFO Philip Johnson emphasized the brand’s unique positioning and slow generic uptake, suggesting continued momentum but withheld specific 2027 guidance.
• Joseph Thome (TD Cowen): focused on the shift in Zepzelca’s sales from second-line to first-line maintenance and its long-term value. Pearce highlighted that first-line maintenance now comprises up to 40% of sales, with second-line usage expected to decline further.
• Leonid Timashev (RBC Capital): queried the strategic rationale for Epidiolex’s additional clinical studies and capsule formulation. CEO Renée Galá and Pearce explained these initiatives as both growth opportunities and methods for increasing patient persistence and market penetration.

Catalysts in Upcoming Quarters

In coming quarters, the StockStory team will closely monitor (1) the approval and commercial launch of zanidatamab for HER2-positive GEA, (2) sustained volume and market share trends for Xywav and Epidiolex—including the impact of new formulations and generic competition, and (3) the progress of ongoing clinical trials and pipeline updates, particularly in rare epilepsy and oncology. The execution of new business development transactions and the effectiveness of targeted investments in commercial capabilities will also be key areas of focus.

Jazz Pharmaceuticals currently trades at $256.63, up from $251.58 just before the earnings. At this price, is it a buy or sell? The answer lies in our full research report (it’s free).

The Best Stocks for High-Quality Investors

WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don’t just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.

But our AI platform says the party isn’t over. Find out which 9 stocks made the cut this week — FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+214% between June 2020 and June 2025). Find your next big winner with StockStory today.